FORWARDHEALTH PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR CYTOKINE AND CELL ADHESION MOLECULE (CAM) ANTAGONIST DRUGS FOR CROHN'S DISEASE

Instructions: Type or print clearly. Before completing this form, read the Prior Authorization/Preferred Drug List (PA/PDL) for Cytokine and Cell Adhesion Molecule (CAM) Antagonist Drugs for Crohn's Disease Completion Instructions, F-11305A. Providers may refer to the Forms page of the ForwardHealth Portal at *www.forwardhealth.wi.gov/WIPortal/Content/provider/forms/index.htm.spage* for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization/Preferred Drug List (PA/PDL) for Cytokine and Cell Adhesion Molecule (CAM) Antagonist Drugs for Crohn's Disease form signed by the prescriber before calling the Specialized Transmission Approval Technology-Prior Authorization (STAT-PA) system or submitting a PA request on the Portal or on paper. Providers may call Provider Services at (800) 947-9627 with questions.

SECTION I — MEMBER INFORMATION						
1. Name — Member (Last, First, Middle Initial)						
2. Member Identification Number	3. Date of Birth — Member					
SECTION II — PRESCRIPTION INFORMATION						
4. Drug Name	5. Drug Strength					
6. Date Prescription Written	7. Directions for Use					
8. Name — Prescriber	9. National Provider Identifier (NPI) — Prescriber					
10. Address — Prescriber (Street, City, State, ZIP+4 Code)						

11. Telephone Number — Prescriber

SECTION III — CLINICAL INFORMATION FOR CROHN'S DISEASE

12. Diagnosis Code and Description

13. Does the member have a diagnosis of Crohn's disease?	Yes	No
14. Does the member have moderate to severe symptoms of Crohn's disease?	Yes	No
15. Is the prescription written by a gastroenterologist or through a gastroenterology consultation?	Yes	No
		Continued

Continued



DT-PA073-073

SECTION III — CLINICAL INFORMATION FOR CROHN'S DISEASE (Continued)									
 16. Has the member received two or more of the drugs listed below and taken each drug for at least three consecutive months and experienced an unsatisfactory therapeutic response or experienced a clinically significant adverse drug reaction? I Yes I No 							No		
If yes, check the boxes next to the drugs the member received. Indicate the dose of the drugs, specific details about the unsatisfactory therapeutic responses or clinically significant adverse drug reactions, and the approximate dates the drugs were taken in the space provided.									
1. 📮 5-aminosalicylic (5-ASA)									
2. 📮 6-mercaptopurine (6MP)									
3. a azathioprine									
4. methotrexate									
5. oral corticosteroids									
6. 📮 sulfasalazine	6. 🗖 sulfasalazine								
SECTION IV — AUTHORIZED SIGNATUR	E								
17. SIGNATURE — Prescriber 18. Date Signed									
SECTION V — FOR PHARMACY PROVID	ERS USING STAT-PA								
19. National Drug Code (11 digits)		20. Days' Supply Requested (Up to 365 Days)							
21. NPI									
22. Date of Service (MM/DD/CCYY) (For STAT-PA requests, the date of service may be up to 31 days in the future or up to 14 days in the past.									
23. Place of Service									
24. Assigned PA Number									
25. Grant Date	26. Expiration Date		27. Number of	imber of Days Approved					
SECTION VI — ADDITIONAL INFORMAT	ION		1						
28. Include any additional information in the product requested may be included here		al diagnostic and clinio	cal information ex	plaini	ing the	need	for the		